清火栀麦片联合重组人白介素-2治疗慢性期布鲁氏菌病患者48例疗效观察

Clinical Efficacy of Qinghuo Zhimai Pill Combined Recombinant Human Interleukin-2 in 48 Cases of Chronic Brucellosis

目的:观察清火栀麦片联合重组人白介素-2治疗慢性期布病的临床疗效。方法:90例慢性期布病患者随机分成2组,其中对照组42例,给予利福平0.6 g,1次/d;多西环素0.1 g,2次/d;6周为1个疗程。观察组48例,在对照组的基础上加用重组人白介素-240万IU,皮下注射,3次/周,6周为1个疗程,同时加用清火栀麦片,4粒/次,3次/d,治疗6周后观察治疗效果。结果:观察组患者近期治愈率为37.5%,基本治愈率为33.3%,好转率为20.8%,无效率为8.4%;而对照组患者近期治愈率为21.3%,基本治愈率为16.7%,好转率为19.5%,无效率为42.5%,前者疗效明显好于后者,2组间比较差异有统计学意义(P<0.05)。2组患者在治疗前,检测的血清IL-1β、IL-6、5-HT及TNF-α含量比较,差异无统计学意义,而组间治疗后比较,观察组明显低于对照组,P<0.05,观察组疗效比对照组好。结论:清火栀麦片联合重组人白介素-2治疗慢性期布病患者具有较好的临床疗效,值得推广。

Objective：To observe the clinical effect of Qinghuo Zhimai Pill combined recombinant human interleukin-2 in the treatment of chronic brucellosis.Methods：Total 90 cases of patients with chronic brucellosis were randomly divided into two groups.The 42 cases in the control group were given rifampicin 0.6 g,once a day,doxycycline 0.1 g,twice a day for 6 weeks.On the basis of the control group＇s treatment,the 48 cases in the control group were given recombinant human interleukin-2 400000 IU for subcutaneous injection three times a week,six weeks for a course,and also Qinghuo Zhimai Pill,4 pills for 3 times each day.After 6 weeks of treatment,therapeutic effects were observed.Results：The curative rate of the observation group was37.5%,basic curative rate was 33.3%,improvement rate was 20.8%,ineffective rate 8.4%;while for the control group,the curative rate was 21.3%,the basic curative rate was 16.7%,improvement rate 19.5%,42.5% was ineffective,the observation group＇s results were significantly better than latter（ P〈0.05）.There were no significant differences on IL-1β,IL-6,5-HT and TNF-α levels between the two groups before the treatment,but after the treatment,there were significant differences（ P〈0.05）.Conclusion：Qinghuo Zhimai Pill combined recombinant human interleukin-2 therapy has clear clinical efficacy in patients with chronic brucellosis,which is worthy of promotion.